Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands

DC ElementWertSprache
dc.contributor.authorMoraga, Ignacio
dc.contributor.authorWernig, Gerlinde
dc.contributor.authorWilmes, Stephan
dc.contributor.authorGryshkova, Vitalina
dc.contributor.authorRichter, Christian P.
dc.contributor.authorHong, Wan-Jen
dc.contributor.authorSinha, Rahul
dc.contributor.authorGuo, Feng
dc.contributor.authorFabionar, Hyna
dc.contributor.authorWehrman, Tom S.
dc.contributor.authorKrutzik, Peter
dc.contributor.authorDemharter, Samuel
dc.contributor.authorPlo, Isabelle
dc.contributor.authorWeissman, Irving L.
dc.contributor.authorMinary, Peter
dc.contributor.authorMajeti, Ravindra
dc.contributor.authorConstantinescu, Stefan N.
dc.contributor.authorPiehler, Jacob
dc.contributor.authorGarcia, K. Christopher
dc.date.accessioned2021-12-23T16:23:38Z-
dc.date.available2021-12-23T16:23:38Z-
dc.date.issued2015
dc.identifier.issn00928674
dc.identifier.urihttps://osnascholar.ub.uni-osnabrueck.de/handle/unios/14611-
dc.description.abstractMost cell-surface receptors for cytokines and growth factors signal as dimers, but it is unclear whether remodeling receptor dimer topology is a viable strategy to ``tune'' signaling output. We utilized diabodies (DA) as surrogate ligands in a prototypical dimeric receptor-ligand system, the cytokine Erythropoietin (EPO) and its receptor (EpoR), to dimerize EpoR ectodomains in non-native architectures. Diabody-induced signaling amplitudes varied from full to minimal agonism, and structures of these DA/EpoR complexes differed in EpoR dimer orientation and proximity. Diabodies also elicited biased or differential activation of signaling pathways and gene expression profiles compared to EPO. Non-signaling diabodies inhibited proliferation of erythroid precursors from patients with a myeloproliferative neoplasm due to a constitutively active JAK2V617F mutation. Thus, intracellular oncogenic mutations causing ligand-independent receptor activation can be counteracted by extracellular ligands that re-orient receptors into inactive dimer topologies. This approach has broad applications for tuning signaling output for many dimeric receptor systems.
dc.description.sponsorshipBELSPO fellowship; de Duve Institute Delori postdoctoral fellowship; Training Program un Investigative Oncology [T32CA009287-35]; Stanford CIRM Training Program [TG2-01159]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01HL099999]; FRS-FNRSFonds de la Recherche Scientifique - FNRS; Salus Sanguinis Foundation; Fondation contre le cancer (Belgium); Program IAP-BeMGI; Program ARCAustralian Research Council; Ludwig Institute; Howard Hughes Medical InstituteHoward Hughes Medical Institute; [NIH-RO1-AI51321]; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [1231073] Funding Source: researchfish; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA086065, T32CA009287] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL099999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R37AI051321, R01AI051321] Funding Source: NIH RePORTER; We thank Kevin Jude for technical assistance; the Division of Hematology Tissue Bank and the patients for donating their samples; Dr. William Vainchenker, Institut Gustave Roussy for providing patient JAK2V617F homozygous CD34+ cells; and Dr. Christian Pecquet for support with cell lines. This work was supported by the BELSPO and de Duve Institute Delori postdoctoral fellowships (V.G.), T32CA009287-35 (Training Program un Investigative Oncology) and TG2-01159 (Stanford CIRM Training Program) (to W.I.H.), NIH U01HL099999 (to G.W., R.S., and I.L.W.), FRS-FNRS, Salus Sanguinis Foundation, Fondation contre le cancer (Belgium), Programs IAP-BeMGI and ARC (S.N.C.), the Ludwig Institute (K.C.G.), NIH-RO1-AI51321 (K.C.G.), and the Howard Hughes Medical Institute (K.C.G.)
dc.language.isoen
dc.publisherCELL PRESS
dc.relation.ispartofCELL
dc.subjectACTIVATING MUTATION
dc.subjectBiochemistry & Molecular Biology
dc.subjectCell Biology
dc.subjectCOMBINATORIAL ANTIBODY LIBRARIES
dc.subjectCRYSTAL-STRUCTURE
dc.subjectERYTHROPOIETIN RECEPTOR
dc.subjectEXTRACELLULAR DOMAIN
dc.subjectHUMAN GROWTH-HORMONE
dc.subjectMONOCLONAL-ANTIBODIES
dc.subjectMYELOPROLIFERATIVE DISORDERS
dc.subjectTHROMBOPOIETIN RECEPTOR
dc.subjectTYROSINE KINASE JAK2
dc.titleTuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands
dc.typejournal article
dc.identifier.doi10.1016/j.cell.2015.02.011
dc.identifier.isiISI:000351951800018
dc.description.volume160
dc.description.issue6
dc.description.startpage1196
dc.description.endpage1208
dc.contributor.orcid0000-0002-5915-6910
dc.contributor.orcid0000-0002-8599-2699
dc.contributor.orcid0000-0001-7352-3994
dc.contributor.orcid0000-0002-4112-710X
dc.contributor.orcid0000-0001-9909-0701
dc.contributor.researcheridC-9056-2017
dc.contributor.researcheridAAT-6742-2021
dc.identifier.eissn10974172
dc.publisher.place600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
dcterms.isPartOf.abbreviationCell
dcterms.oaStatusBronze, Green Accepted
crisitem.author.deptFB 05 - Biologie/Chemie-
crisitem.author.deptidfb05-
crisitem.author.orcid0000-0002-2143-2270-
crisitem.author.parentorgUniversität Osnabrück-
crisitem.author.netidPiJa938-
Zur Kurzanzeige

Seitenaufrufe

1
Letzte Woche
0
Letzter Monat
0
geprüft am 15.05.2024

Google ScholarTM

Prüfen

Altmetric